Dynamic Technology Lab Private Ltd Invests $871,000 in HealthEquity, Inc. (NASDAQ:HQY)

Dynamic Technology Lab Private Ltd bought a new stake in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 13,136 shares of the company's stock, valued at approximately $871,000.

A number of other large investors also recently added to or reduced their stakes in the business. FMR LLC raised its position in shares of HealthEquity by 19.1% in the 3rd quarter. FMR LLC now owns 5,648,992 shares of the company's stock valued at $412,659,000 after acquiring an additional 907,743 shares during the period. Clearbridge Investments LLC raised its position in shares of HealthEquity by 12.1% in the 3rd quarter. Clearbridge Investments LLC now owns 2,204,675 shares of the company's stock valued at $161,051,000 after acquiring an additional 238,116 shares during the period. Mackenzie Financial Corp raised its position in shares of HealthEquity by 58.2% in the 4th quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company's stock valued at $119,831,000 after acquiring an additional 664,979 shares during the period. Dimensional Fund Advisors LP raised its position in shares of HealthEquity by 8.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,409,740 shares of the company's stock valued at $93,466,000 after acquiring an additional 108,108 shares during the period. Finally, Van Berkom & Associates Inc. raised its position in shares of HealthEquity by 5.2% in the 3rd quarter. Van Berkom & Associates Inc. now owns 1,042,470 shares of the company's stock valued at $76,152,000 after acquiring an additional 51,824 shares during the period. 99.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other HealthEquity news, CEO Jon Kessler sold 33,765 shares of the business's stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $79.81, for a total transaction of $2,694,784.65. Following the completion of the transaction, the chief executive officer now owns 126,635 shares of the company's stock, valued at $10,106,739.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Jon Kessler sold 33,765 shares of the company's stock in a transaction that occurred on Friday, March 22nd. The stock was sold at an average price of $79.81, for a total value of $2,694,784.65. Following the completion of the transaction, the chief executive officer now owns 126,635 shares of the company's stock, valued at $10,106,739.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Evelyn S. Dilsaver sold 32,500 shares of the company's stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $79.29, for a total value of $2,576,925.00. Following the completion of the transaction, the director now directly owns 32,123 shares of the company's stock, valued at approximately $2,547,032.67. The disclosure for this sale can be found here. Insiders sold 68,823 shares of company stock valued at $5,482,975 over the last quarter. 2.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. JMP Securities assumed coverage on HealthEquity in a research note on Thursday, April 4th. They set a "mkt outperform" rating and a $101.00 target price for the company. JPMorgan Chase & Co. raised their price target on shares of HealthEquity from $86.00 to $108.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 2nd. BTIG Research raised their price target on shares of HealthEquity from $100.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. KeyCorp raised their price target on shares of HealthEquity from $85.00 to $95.00 and gave the stock an "overweight" rating in a research note on Friday, March 22nd. Finally, Barrington Research reaffirmed an "outperform" rating and set a $100.00 price target on shares of HealthEquity in a research note on Friday, March 22nd. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $96.17.

HealthEquity Stock Performance

Shares of HealthEquity stock traded up $0.15 during trading on Wednesday, reaching $79.46. The company's stock had a trading volume of 439,866 shares, compared to its average volume of 586,040. The business's 50-day moving average price is $79.86 and its 200-day moving average price is $75.30. The firm has a market cap of $6.91 billion, a PE ratio of 124.16, a P/E/G ratio of 1.29 and a beta of 0.55. HealthEquity, Inc. has a 52 week low of $54.09 and a 52 week high of $84.49. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.43.

HealthEquity (NASDAQ:HQY - Get Free Report) last announced its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.08. The company had revenue of $262.39 million during the quarter, compared to analysts' expectations of $258.56 million. HealthEquity had a net margin of 5.57% and a return on equity of 6.91%. Equities analysts forecast that HealthEquity, Inc. will post 2.12 earnings per share for the current year.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.